Keyword: Olumiant (baricitinib)
Sanofi and Regeneron's Dupixent could be on its way to €10 billion a year, but pushback from England's cost watchdog in severe asthma won't help.
With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, another Incyte med is also looking for a win in that indication.
Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?
ICER is still concerned about high prices of next-generation RA drugs—a stance that's not going over well among RA drugmakers and patient groups.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.
Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past. But can they stop the drugmakers from adding another indication?
JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.
Pfizer’s Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s high-dose hopes in RA. Could new data help the cause?
Eli Lilly and Incyte’s Olumiant path has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Can new safety data help?